CDEK by Data4ThePeople
Sign in Sign up
← All drugs Report issue

oregovomab

mAbexperimental

Oregovomab is a mouse monoclonal antibody it binds to the antigen CA125, a carbohydrate antigen. It is designed for the treatment of ovarian cancer. — Wikipedia

Clinical trial activity

17 trials · 19 clinical orgs · 0 marketing orgs

Phase 1
5
Phase 2
15
Phase 3
2
Phase 4
0

Earliest trial started Apr 1, 1998 (NCT00003634)

Timeline

1990s

  1. Jan 1, 1998

    Earliest Phase 2 Sponsor(trial)

2000s

  1. Jan 1, 2002

    Earliest Phase 1 Sponsor(trial)

  2. Jan 1, 2002

    Earliest Phase 3 Sponsor(trial)

Indications

Studied for

Mechanism of action

  • Mucin-16OTHER

    MUC16 other

    Oregovomab targets the circulating tumour-associated antigen CA125. The complex formation of MAb-B43.13 with CA125 appears to facilitate activation of immune specific B and T Cell responses to CA125, otherwise not recognised by the immune system.

  • Tumor antigensImmunity, passive

    Tumor antigens immunity, passive

Chemistry & pharmacology

Chirality
Single Stereoisomer
Inorganic
No
Polymer
No
Multi-specific
No

Oral

No

Parenteral

No

Topical

No

Sources

Also known as

  • b43.13
  • mab b43.13
  • mab-b43.13
  • moab b43.13
  • monoclonal antibody b43.13
  • monoclonal antibody b43.13
  • oregovamab
  • oregovamab
  • oregovomab
  • oregovomab
  • oregovomab
  • oregovomab
  • ovarex
  • ovarex

Clinical trials

NCT IDPhaseStart dateSponsor(s)
NCT05605535Phase 2Dec 12, 2022CanariaBio Inc., Raptim Research
NCT05335993Phase 2Jul 25, 2022CanariaBio Inc., Veristat, Inc.
NCT05407584Phase 2Jul 5, 2022CanariaBio Inc., Yonsei University
NCT04938583Phase 1/Phase 2 (Phase 2)Mar 17, 2021OncoQuest Pharmaceuticals Inc., Seoul National University, University of Ulsan
NCT04620954Phase 1/Phase 2 (Phase 2)Oct 7, 2020Bristol-Myers Squibb, Government of Singapore, Quest PharmaTech Inc.
NCT04498117Phase 3Aug 25, 2020Gynecologic Oncology Group, IQVIA, OncoQuest Pharmaceuticals Inc.
NCT03162562Phase 1May 1, 2017AIT Strategies, Quest PharmaTech Inc.
NCT03100006Phase 1/Phase 2 (Phase 2)Feb 22, 2017Government of Singapore
NCT01959672Phase 2Sep 1, 2013National Cancer Institute (NCI), University of Nebraska
NCT01616303Phase 2Jun 1, 2012AIT Strategies, Quest PharmaTech Inc.
NCT00551265N/AOct 1, 2007Gynecologic Oncology Group, National Cancer Institute (NCI)
NCT00086632Phase 2Jul 1, 2004Unither Pharmaceuticals
NCT00050375Phase 3Dec 1, 2002Unither Pharmaceuticals
NCT00034138Phase 1/Phase 2 (Phase 2)Mar 1, 2002Unither Pharmaceuticals
NCT00034372Phase 2Sep 1, 2000Unither Pharmaceuticals
NCT00004064Phase 2Nov 1, 1998AltaRex, Temple University
NCT00003634Phase 2Apr 1, 1998AltaRex, University of California, Los Angeles
Showing 17 of 17 trials
Page 1 / 1

Organizations

Research & Development (19)

OrganizationOrg typeTrialsAs lead sponsorPhasesEarliest year
Unither PharmaceuticalsFor profit4422000
CanariaBio Inc.For profit3212022
Quest PharmaTech Inc.For profit3222012
AIT StrategiesAcademic/Hospital2022012
AltaRexFor profit2211998
Government of SingaporeGovernment2212017
Gynecologic Oncology GroupAcademic/Hospital2122007
National Cancer Institute (NCI)Government2022007
OncoQuest Pharmaceuticals Inc.For profit2222020
Bristol-Myers SquibbFor profit1012020
IQVIAFor profit1012020
Raptim ResearchFor profit1012022
Seoul National UniversityAcademic/Hospital1012021
Temple UniversityAcademic/Hospital1011998
University of California, Los AngelesAcademic/Hospital1011998
University of NebraskaAcademic/Hospital1112013
University of UlsanAcademic/Hospital1012021
Veristat, Inc.For profit1012022
Yonsei UniversityAcademic/Hospital1112022
19 organizations
Page 1 / 1